Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 13;14:7329. doi: 10.1038/s41467-023-43123-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a Expression of top ranked disease status related imageable genes in malignant ovarian epithelial cells over time: at diagnosis (pre-treatment), under therapy (treatment), and in relapse as indicated by an augmented serum CA-125 level (two-sided Wilcox test). b Tissue origins during lung cancer metastasis and top ranked imageable genes differentially expressed at advanced or metastatic sites versus primary site, two-sided Student’s t test p < 0.01 with Bonferroni correction<0.01, |log2(fold change)|>0.585. c Top diagnostic imageable genes across 5 cancer types. log2(fold change)>0.5 and Limma moderated t-statistic with Bonferroni correction<0.01. (i) heatmap illustrating the gene expressions (columns) in normal or cancer tissue (rows); (ii) an gene of interest (GOI) in mauve with a chemical structure of PET radiotracer targeting the GOI; (iii) violin plot of GOI expression in bone (n = 284), liver (n = 1759) and mammary cancer (n = 5541), kidney cancer (n = 349) or intestines cancer (n = 2227), two-sided Wilcoxon test p values are shown. (iv) ROC curves of GOI and SLC2A1 with 95% confidence interval (CI) and two-sided DeLong’s test p value for two correlated ROC curves. d A schematic showing the predictive capacity (ROC curves, sensitive: PD1-blockage treatment responder, resistant: non-responders) of 5 representative imageable genes, and their clinical radiotracers. e Prognostic imageable genes in, left to right, Cervix cancer, Colon cancer and Hepatocellular cancer. For each cancer, (i) top ranked imageable genes sorted by p values from Wald test by fitting Cox proportional hazards (CPH) models to evaluate the effect of covariates on overall survival, with the best cutoff determined (see “Methods”). A square represents the Hazard Ratio (HR) with a horizontal line extending on either side representing the 95% CI. GOI is labelled in mauve. *p < 0.05; **p < 0.01; ***p < 0.001; (ii) Kaplan–Meier overall survival with Log-Rank test p value; (iii) cox regression overall survival curves distinguishing GOI high/low expression groups (multivariable survival analyses with Wald test p values by fitting CPH model); (iv) chemical structure of PET radiotracer targeting the GOI. Cancer-type icons are created with BioRender.com. Source data are provided as a Source data file.